PDGFRB and glioblastoma: We show that targeting EGFRvIII by CL4 causes upregulation of PDGFRβ and that CL4 and gefitinib cooperate with a validated anti-PDGFRβ aptamer [22] in inhibiting EGFRvIII-positive GBM cells growth.